CHLORMERODRIN HG 197
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLORMERODRIN HG 197 is a radioactive diagnostic agent containing mercury-197, developed by Bracco and approved in 1974. The drug is administered via injection and used for diagnostic imaging purposes. The specific clinical indications are not documented in available data.
LOE Approaching
Approaching loss of exclusivity with minimal current commercial infrastructure, signaling potential downsizing or transition planning for remaining team members.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This legacy diagnostic product offers minimal career growth, with zero linked job openings. Career roles are primarily focused on product maintenance, compliance, and orderly transition or discontinuation. Working on CHLORMERODRIN HG 197 represents a legacy support function rather than a growth opportunity.
Product Manager (Legacy/Lifecycle)Regulatory Affairs Specialist
Worked on CHLORMERODRIN HG 197 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.